CLDI — Calidi Biotherapeutics Share News
0.000.00%
Last trade - 00:00Brief: Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval
Brief: Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public Offering
Brief: Calidi Biotherapeutics Eliminates Chief Legal Officer Position - SEC Filing
Brief: Calidi Biotherapeutics Receives FDA Fast Track Designation For Cld-201 (Supernova), A First-In-Class Stem-Cell Loaded Viral Therapy For The Treatment Of Patients With Soft Tissue Sarcoma
Brief: Calidi Biotherapeutics - On July 24, Eliminates President, Medical And Scientific Affairs Position - SEC Filing
Brief: Calidi Biotherapeutics Announces Shareholder Letter From CEO
Brief: Calidi Biotherapeutics Reports First Quarter 2025 Financial Results And Recent Operational Highlights
Brief: Calidi Biotherapeutics Announces Chief Executive Officer Transition And Appointment Of Eric Poma, Ph.D. As CEO And Director
Brief: Calidi Biotherapeutics Announces FDA Clearance Of IND Application For Cld-201 In Solid Tumors
Brief: Calidi Biotherapeutics And City Of Hope Provide Update On A Phase 1 Clinical Trial With CLD-101 Virotherapy In Patients With Recurrent High-Grade Glioma
Brief: Calidi Biotherapeutics Announces Closing Of $4.25 Million Public Offering Of Common Stock
Brief: Calidi Biotherapeutics Inc Files For Mixed Shelf Of Up To $25 Million - SEC Filing
Brief: Calidi Biotherapeutics Prices $4.25 Million Public Offering Of Common Stock
Brief: Calidi Biotherapeutics Announces Closing Of $7.5 Million Public Offering Of Common Stock
Brief: Calidi Biotherapeutics Announces Pricing Of $2 Mln Registered Direct Offering And Concurrent Private Placement
Brief: Calidi Biotherapeutics NYSE American To Commence Delisting Proceedings With Respect To Warrants Of Co
Brief: Calidi Biotherapeutics Inc Says Co Entered Into Sales Agreement With Ladenburg Thalmann & Co. Inc
Brief: Calidi Biotherapeutics Inc Files For Mixed Shelf Offering Of Up To $25 Million - SEC Filing
Brief: Calidi Biotherapeutics Announces FDA Clearance Of Northwestern University's IND Application For CLD-101 Clinical Trial